KRT20 Antibody

說(shuō)明書

中文名稱：

KRT20兔多克隆抗體
貨號(hào)：

CSB-PA002048
規(guī)格：

￥1090
圖片：
Western Blot analysis of HeLa cells using Cytokeratin 20 Polyclonal Antibody
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

P35900
基因名：

KRT20
別名：

CD20 antibody; CK 20 antibody; CK-20 antibody; CK20 antibody; Cytokeratin-20 antibody; Cytokeratin20 antibody; K1C20_HUMAN antibody; K20 antibody; KA20 antibody; Keratin 20 antibody; keratin 20, type I antibody; keratin 21, rat, homolog of antibody; Keratin antibody; Keratin type I cytoskeletal 20 antibody; Keratin-20 antibody; Keratin20 antibody; KRT 20 antibody; KRT 21 antibody; KRT20 antibody; KRT21 antibody; MGC35423 antibody; OTTHUMP00000164518 antibody; Protein IT antibody; type I cytoskeletal 20 antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Synthesized peptide derived from the C-terminal region of Human Cytokeratin 20.
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

WB, IHC, IF, ELISA

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:100-1:300
IF	1:200-1:1000
ELISA	1:10000

Protocols：

Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
ELISA Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Plays a significant role in maintaining keratin filament organization in intestinal epithelia. When phosphorylated, plays a role in the secretion of mucin in the small intestine.
基因功能參考文獻(xiàn)：
1. Carcinoid-like/labyrinthine pattern of cell arrangement in vimentin/cytokeratin 20 expressing sebaceous neoplasms may represent a morphological phenotype of sebaceous mantles. PMID: 28027080
2. In our cohort of specimens with equivocal urothelial atypia, very few patients without a prior diagnosis of bladder cancer progressed to diagnostic cancer (1 of 22), suggesting that CK20 and p53 staining results should be interpreted with caution in de novo atypia. PMID: 28967804
3. results demonstrate the diagnostic value of urinary cytology and confirm CK 20 as an adjunct marker for the diagnosis of urothelial carcinoma. PMID: 28195264
4. findings of our study imply that sequential staining of CK20 and E-cadherin prevents false-positive classification of BCC. Furthermore, our study demonstrated that p40 exhibits the same staining pattern in BCC, TE, and TB PMID: 26180934
5. In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively. PMID: 28029907
6. results demonstrated upregulation of fibroblast growth factor receptor 1 and CK20 expressions in cancer bladder tissues PMID: 27259667
7. K20 expression was detected in 6 of 75 patients with triple-negative carcinoma PMID: 26670478
8. Circulating tumor cell CK20 and survivin expression may effectively predict overall survival in metastic colorectal cancer patients receiving chemotherapy. PMID: 26227487
9. During postoperative follow-up, serum negative CK20 patients had significantly higher 3-year survival rates than serum positive CK20 patients. PMID: 26125781
10. Patients with any EGFR, CK19, CK20 or survinin positivity in their peripheral blood obtain less benefit from radiotherapy. PMID: 25854400
11. Case Report: Merkel cell carcinma that initially demonstrated cytokeratin 20 positivity but lost expression in subsequent brain metastases. PMID: 24901475
12. Our data show that inclusion of CK20 as a biomarker efficiently improves the detection of CTCs in colorectal cancer patients PMID: 25528628
13. The present study confirmed that CK14, but not CK20 or CK7, is expressed in urothelial carcinoma with squamous differentiation and squamous cell carcinoma of the urinary bladder. PMID: 25643514
14. Immunostaining of CDX2 and CK20 provides beneficial information if considering whether to perform an endoscopic papillectomy (EP). PMID: 25081540
15. High cytokeratin 20 expression is associated with invasive histological phenotype in poorly differentiated colorectal adenocarcinoma. PMID: 24403457
16. Its association with clinical stage indicates that CK20 might have prognostic value as a marker for detection of circulating CRC cells. PMID: 23558939
17. The CDX2/CK20 phenotype defines a distinct subgroup of colorectal cancers with microsatellite instability and poor differentiation PMID: 24025523
18. Data show that lower survival (OS) and disease-free survival (DFS) rates were significantly associated with guanylate cyclase C (GCC) and CK20 mRNA levels. PMID: 23150200
19. Overexpression of CK20 is associated with early-onset colorectal cancer. PMID: 23322277
20. High cytokeratin 20 mrna expression is associated with lymphatic metastasis in colon cancer. PMID: 22752373
21. Pouch/peripouch and UC-associated adenocarcinoma had a comparable positive rate for CK7, CK20, and CDX2 by immunohistochemistry. PMID: 22895272
22. HER2 and CK20 were seen exclusively in the mucinogenic proliferations in congenital pulmonary airway malformations. PMID: 22348416
23. CEA mRNA, CK20 mRNA, and serum CEA than patients at stages I-III. PMID: 22414974
24. Results suggest that CK20 mRNA with other biomarkers in the peripheral blood of breast cancer patients may be useful to monitor the presence of disseminated tumor cells in the blood circulation and to predict the prognosis of breast cancer. PMID: 22677992
25. Both the CK7-/CK20+ phenotype and expression of the antibody CDX2 are highly specific and sensitive markers of colorectal origin. PMID: 22268990
26. This is the first reported study of the relationship between CK20/CK7 immunophenotype, BRAF mutations and microsatellite status in colorectal carcinomas PMID: 22361037
27. positivity rates of CK19 and CK20 in transverse mesocolon were 48.6 and 61.2%, respectively and increased with the depth of tumor invasion PMID: 21938557
28. Keratin 20 expression is common in colorectal carcinoma. PMID: 22237712
29. The expressions of CK7 and CK20 in nasal polyps were analyzed. PMID: 22119824
30. Cytokeratin 20-positive hepatocellular carcinoma PMID: 22073364
31. CK20 and VEGF expressions in peripheral blood of colorectal carcinoma patients are promising molecular markers for disease progression and metastasis. PMID: 20395351
32. Merkel cell carcinoma admixed with squamous cell carcinoma can be cytokeratin 20-negative and thyroid transcription factor-1-positive [case report] PMID: 21775107
33. Our results along with the data from the literature indicate that CK7/CK20 expression may be of clinical significance. PMID: 21574103
34. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. PMID: 21677534
35. A considerable number of colorectal carcinomas showed no immunoreactivity to CK20. PMID: 21282015
36. The immunohistochemical subtypes based on CK20and MUC1 expression correlated with ampullary tumor progression. PMID: 21106111
37. Case Report: CK7+/CK20- Merkel cell carcinoma presenting as inguinal subcutaneous nodules with subsequent epidermotropic metastasis. PMID: 20574624
38. MMP-11 and CK-20 are probable prognostic markers whose expression reflects the stages of tumor differentiation and LNM of breast cancer. PMID: 19914229
39. CK20 expression is associated with the progression of breast cancer. PMID: 19664394
40. The expression level of CK20 mRNA in the peripheral blood in patients with gastric cancer declines after postoperative adjuvant chemotherapy. PMID: 19145500
41. CK20 expression modified in H. pylori chronic gastritis PMID: 11642721
42. expression in lymph nodes correlates with poor prognosis in colorectal cancer PMID: 11844829
43. expression pattern is unique to Barrett's esophagus PMID: 11857318
44. Changing pattern of cytokeratin 7 and 20 expression from normal epithelium to intestinal metaplasia of the gastric mucosa and gastroesophageal junction PMID: 11962749
45. The detection of cancer metastasis in the lymph nodes in colon carcinoma is almost doubled (21.9% vs 11.1%) by CK-20 mRNA PMID: 12515621
46. CK 20 mRNA identification by RT-PCR is reliable and may be useful for early diagnosis in peritoneal dissemination of colon cancer PMID: 12636102
47. It is possible to apply a simple and reliable method for the detection of circulating tumor cells based on cytokeratin-20 and prostate stem cell antigen RT-PCR assays in gastrointestinal cancers. PMID: 12894563
48. Down regulation of cytokeratin 20 is associated with transitional and squamous cell carcinoma of the bladder PMID: 12954496
49. The combined expression of CK7 and CK20 has a low specificity in the distinction between esophageal and cardiac (stomach) adenocarcinomas. PMID: 14631371
50. Alteration of CK7 and CK20 expression profile that occurs early in small intestinal tumorigenesis. PMID: 15371952
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm.
蛋白家族：

Intermediate filament family
組織特異性：

Expressed predominantly in the intestinal epithelium. Expressed in luminal cells of colonic mucosa. Also expressed in the Merkel cells of keratinized oral mucosa; specifically at the tips of some rete ridges of the gingival mucosa, in the basal layer of t
數(shù)據(jù)庫(kù)鏈接：

HGNC: 20412

OMIM: 608218

KEGG: hsa:54474

STRING: 9606.ENSP00000167588

UniGene: Hs.84905

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human